BullFrog AI Founder and CEO Vin Singh to Deliver Keynote at AIDDD Summit
BullFrog AI (BFRG) announced that founder and CEO Vin Singh will deliver the keynote at the AI Drug Discovery & Development Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BullFrog AI (BFRG) announced that founder and CEO Vin Singh will deliver the keynote at the AI Drug Discovery & Development Summit. The presentation, titled “AI Drug Discovery: How Far We've Come,” is scheduled for October 27, 2026, at 5:30 p.m. Eastern Time in Boston. Singh will discuss AI's progress in drug discovery, early clinical findings across the industry and challenges in later-stage development. He will also explore how discovery efficiencies translate into overall development costs, clinical success rates and patient outcomes.
Key Terms
phase i medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Keynote to explore the progress and remaining challenges of AI in drug discovery and development
GAITHERSBURG, Md., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI"), an AI company using its proprietary platform to turn complex biomedical data into actionable insights, today announced that Vin Singh, Founder and Chief Executive Officer, will deliver the keynote at the AI Drug Discovery & Development (“AIDDD”) Summit today, October 27, 2026, at 5:30 p.m. Eastern Time in Boston.
The keynote, titled “AI Drug Discovery: How Far We've Come,” will examine the progress of artificial intelligence in drug discovery and development, including accelerated discovery timelines, reduced early-stage costs and the growing number of AI-derived drug candidates entering clinical trials.
Mr. Singh will also discuss emerging clinical results from AI-discovered drug candidates across the industry, including encouraging Phase I findings and the challenges that remain in later-stage development. Additionally, Mr. Singh will explore how early discovery efficiencies translate into lower overall development costs, clinical success rates and patient outcomes.
Drawing on his experience founding BullFrog AI more than nine years ago, Mr. Singh will offer his perspective on the evolution of AI, the importance of combining advanced technologies with scientific expertise, and the need to measure the industry's achievements through demonstrated results rather than technological promise alone. The keynote will also emphasize the opportunity for AI to enhance human decision-making, improve the probability of successful drug development and ultimately help bring better medicines to patients.
About BullFrog AI
BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated. BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP™ for biology-aware data harmonization, bfLEAP® for causal AI analytics and patient subgroup discovery, and bfARENAS™ for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.
For more information visit BullFrog AI at: https://bullfrogai.com.
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Investors:
Erika Schultz
ir@bullfrogai.com
Media:
pr@bullfrogai.com
